Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus

American Journal of Health-System Pharmacy

Volumn 54, Issue 10, 1997, Pages 1191-1193

  Gabriel, Caroline M ^a,b   Minor, James R ^b,c   Vogel, Susan ^d   Piscitelli, Stephen C ^b,d  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; IBUPROFEN; LOPERAMIDE; LORAZEPAM; ONDANSETRON; OXYCODONE; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; RECOMBINANT INTERLEUKIN 2; TEMAZEPAM;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG COST; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; VOMITING;

EID: 0030992624     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.10.1191     Document Type: Article

References (5)

1. Schwartz DH, Merigan TC. Interleukin-2 in the treatment of HIV disease. Biotherapy. 1990; 2:119-36.
2. Rook AH, Masur H, Lane HC et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983; 72:398-403.
3. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993; 46:446-514.
4. Red book. Doherty MC, ed. Montvale, NJ: Medical Economics; 1995.
5. Kovacs JA, Vogel S, Albert JM et al. Controlled trial of interleukin-2 infusions in patients infected with human immunodeficiency virus. N Engl J Med. 1996; 335:1350-6.